Department of Veterans Affairs Awarded a Contract to BIOMERIEUX INC for $182,279.48

Summary of Award

The JSON response from usaspending.gov outlines the specifics of a federal government contract awarded to BioMérieux Inc. by the Department of Veterans Affairs (VA). The contract, identified by award ID "36C26125N0449," signifies a Blanket Purchase Agreement (BPA) call aimed at procuring in vitro diagnostic substances, reagents, test kits, and sets—a pivotal part of medical and laboratory supplies vital for the VA's healthcare operations.

**Overview of the Contract:**

Awarded on April 10, 2025, this contract has a total obligation of $182,279.48. The description succinctly identifies its purpose: "VISN 21 WIDE FILM ARRAY LABORATORY TEST SYSTEM COST PER TEST," indicating the supply of diagnostic testing systems across the Veterans Integrated Service Network (VISN 21). **Award Structure:** This BPA call falls under an overarching BPA contract signed previously between the Department of Veterans Affairs and BioMérieux Inc. The agency awarded the contract through "FULL AND OPEN COMPETITION," ensuring a competitive procurement process. Such a process encourages transparency and optimal allocation of government funds while promoting fair competition among potential suppliers. The contract is classified under NAICS code "325413," denoting "In-Vitro Diagnostic Substance Manufacturing." This classification aligns with BioMérieux's expertise in producing diagnostic substances crucial for meeting the VA's medical diagnostic needs. **Timeline and Execution:** The period of performance for the contract is specified from July 1, 2025, to January 31, 2026. This timeline suggests a strategic approach to supplying the necessary laboratory test systems within a specific timeframe, ensuring that the VA's services remain uninterrupted. **About BioMérieux Inc.:** BioMérieux Inc., the contract recipient, is recognized as a corporate entity that is not tax-exempt and is foreign-owned yet incorporated in the U.S. The company operates within the "Manufacturer of Goods" business category and is not designated as a small business. Based in Salt Lake City, Utah, BioMérieux is well-poised to supply laboratory testing systems due to its specialization in in-vitro diagnostics. As a global leader in its field, BioMérieux is renowned for its innovative solutions that enhance patient care. The company's product lines typically include test kits and diagnostic substances meeting a wide array of medical and laboratory needs. This expertise makes BioMérieux a fitting partner for the VA's objectives in healthcare delivery. **Transaction Details:** The contract has so far recorded one transaction on April 10, 2025, amounting to $182,279.48, reflecting the full obligation of the contract. This transaction highlights the financial commitment undertaken by the VA for this procurement. The absence of any modifications (Mod "0") suggests a straightforward execution, adhering to the initially agreed terms. **Agency Involvement:** Both the funding and awarding of the contract were managed by the VA through its Network Contract Office 21 (36C261). The VA's consistent management throughout signifies streamlined coordination from funding to execution, facilitating efficient procurement processes. **Implications for Government Spending and Policy:** The awarding of this contract is illustrative of the government's commitment to maintaining and enhancing the healthcare services available to veterans. By choosing to work with a prominent entity like BioMérieux, the VA ensures that its facilities are equipped with cutting-edge diagnostic technologies. In turn, this supports the VA's overarching mandate to deliver high-quality and timely healthcare to veterans across various states. The use of a BPA call within the context of a larger agreement provides flexibility in the procurement process, enabling the VA to respond swiftly to replenishment needs without initiating lengthy procurement cycles. This mechanism underscores the efficient use of taxpayer funds, striving to achieve maximum value and quality in government spending. **Conclusion:** This contract between the VA and BioMérieux Inc. is a testament to strategic procurement practices and effective allocation of resources. By procuring state-of-the-art diagnostic substances and systems, the VA not only strengthens its healthcare infrastructure but also aligns with federal goals of transparency, competitiveness, and efficiency in public spending. Overall, this contract serves as an exemplar of how government expenditure is directed towards improving healthcare services for veterans, reinforcing the critical role these investments play in national policy and welfare.